Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies
Saini, Kamal S., Tagliamento, Marco, Lambertini, Matteo, McNally, Richard, Kelly, Adrianne, Romano, Marco, Chico, Isagani, Jenson, Taylor, Anderson, Steven M, Curigliano, Giuseppe, de Azambuja, Evandro
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer
Yap, Timothy A., Basu, Cynthia, Goldman, Jonathan W., Gordon, Michael, Hamilton, Erika, Kelly, Adrianne, Liu, Feng, Moreau, Allison R., Neumann, Heather, Papadopoulos, Kyriakos, Rugo, Hope S., Shapiro, Geoffrey I., Vinayak, Shaveta, Zhou, Li, Jhaveri, Komal
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
Schram, Alison, Spreafico, Anna, Oliva, Marc, Brana, Irene, Garralda, Elena, Lakhani, Nehal, Hoff, Daniel Von, Borazanci, Erkut, Pandya, Naimish, Hoffman, Kimberly, Hallett, Robin, Giblin, Patricia, Anido, Judit, Kelly, Adrianne, Wasserman, Robert, Seoane, Joan, Siu, Lillian, Hyman, David M., Tabernero, Josep
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
Schram, Alison, Borazanci, Erkut, Brana, Irene, Villar, Maria Vieito, Garralda, Elena, Spreafico, Anna, Oliva, Marc, Lakhani, Nehal, Wasserman, Robert, Hoffmann, Kimberly, Hallett, Robin, Anido, Judit, Maetzel, Dorotea, Giblin, Patricia, Moran, Enda, Kelly, Adrianne, Seoane, Joan, Von Hoff, Daniel D., Siu, Lillian, Tabernero, Josep
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma
Brown, Jennifer R, Davids, Matthew S., Rodon, Jordi, Abrisqueta, Pau, DeCillis, Arthur P., Rockich, Kevin, Egile, Coumaran, Kelly, Adrianne, Xu, Yi, Lager, Joanne, Awan, Farrukh T
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma
Papadopoulos, Kyriakos P, Abrisqueta, Pau, Chambers, Glenda, Rasco, Drew, Patnaik, Amita, Tabernero, Josep, Rajangam, Kanya, Rockich, Kevin, Egile, Coumaran, Kelly, Adrianne, Xu, Yi, Lager, Joanne, Vose, Julie M
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article